MetaCap

Bausch + Lomb (BLCO) vs National Vision (EYE)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Bausch + Lomb (BLCO) has outperformed National Vision (EYE) over the past year, gaining 28.6% versus a loss of 37.1%. Bausch + Lomb is the larger company by market cap ($6.93 billion vs $1.31 billion), about 5.3 times the size, while National Vision is growing revenue faster (+9.0% vs +6.5%). On valuation, National Vision trades at a lower forward P/E (14.3x vs 16.4x for Bausch + Lomb).

National Vision converts more of its revenue into profit, with a net margin of 1.5% versus -7.1%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BLCO+28.60%EYE-37.12%
+46%-0%-46%
Nov 21, 20251 yearNov 20, 2026
BLCO-3.10%EYE-52.85%
+25%-26%-77%
May 2, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BLCO versus EYE key metrics
MetricBLCOEYE
Share price$19.38$16.72
Market cap$6.93B$1.31B
1-day change-6.33%-1.70%
YTD return+13.47%-35.24%
1-year return+28.60%-37.12%
5-year return—-65.00%
P/E ratio (TTM)—20.39
Forward P/E16.3614.31
EPS (TTM)$-0.32$0.82
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$5.10B$1.99B
Revenue growth (YoY)+6.47%+9.00%
Net income (latest FY)$-360.00M$29.60M
Gross margin—58.77%
Operating margin2.22%2.96%
Net margin-7.06%1.49%
52-week high$21.40$30.02
52-week low$14.65$14.75
Distance from 52-week high-9.44%-44.30%
Analyst consensusbuybuy
Avg. price target upside+13.16%+61.48%
Average volume660.67K2.14M
Shares outstanding357.50M78.07M
Employees13,00013,138
SectorHealth CareHealth Care
IndustryOphthalmic GoodsOphthalmic Goods

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Bausch + Lomb is about 5.3 times larger than National Vision by market value ($6.93B vs $1.31B).
  • BLCO has outperformed EYE by 65.7 percentage points over the past year.
  • National Vision is more profitable, keeping 1.5 cents of every revenue dollar as net income versus -7.1 cents for Bausch + Lomb.

About Bausch + Lomb

BLCO stock →

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical.

Health Care · Ophthalmic Goods · 13,000 employees

About National Vision

EYE stock →

National Vision Holdings, Inc., through its subsidiaries, operates as an optical retailer in the United States. The company offers eyeglasses and contact lenses, and optical accessory products; and provides eye exams through its America's Best, Eyeglass World, Vista Optical, Fred Meyer, Vista Optical military, and DiscountContacts.com.

Health Care · Ophthalmic Goods · 13,138 employees

BLCO vs EYE FAQ

Which is bigger, Bausch + Lomb or National Vision?

Bausch + Lomb (BLCO) is larger, with a market capitalization of $6.93B compared with $1.31B for National Vision (EYE).

Which stock has performed better over the past year, BLCO or EYE?

BLCO returned +28.60% over the past 12 months, compared with -37.12% for EYE (price return, excluding dividends). Past performance does not predict future results.

Are Bausch + Lomb and National Vision in the same industry?

Yes. Both are classified in the Ophthalmic Goods industry within the Health Care sector.

More comparisons